In Group 1 of 60 patients, desflurane inhalational agent was administered continuously during coronary artery bypass graft surgery with cardiopulmonary bypass. Anesthesia induction was administered to all patients with intravenous midazolam at a dose of 0.2 mg/kg, fentanyl at a dose of 5 to 10 µg/kg and rocuronium bromide at a dose of 0.1 mg. For maintenance, in Group 1 patients, desflurane inhalational agent was administered at an end-tidal concentration of 1 to 4% during the whole surgical procedure and intravenous maintenance midazolam at a dose of 0.03 mg/kg and fentanyl at a dose of 1 to 2 µg/kg every half an hour. In Group 1 of patients, during the whole surgical procedure, attention to keep mean arterial pressure above 50 mmHg was provided.

In Group 2 of 60 patients, desflurane inhalational agent was administered intermittently during coronary artery bypass graft surgery with cardiopulmonary bypass. Anesthesia induction was administered to all patients with intravenous midazolam at a dose of 0.2 mg/kg, fentanyl at a dose of 5 to 10 µg/kg and rocuronium bromide at a dose of 0.1 mg/kg. For maintenance, in Group 2 patients, desflurane inhalational agent was administered at an end-tidal concentration of 1 to 4% before and after the cardiopulmonary bypass procedure as intermittently with the addition of intravenous maintenance midazolam at a dose of 0.03 mg/kg and fentanyl at a dose of 1 to 2 µg/kg every half an hour. In Group 2 of patients, during the whole surgical procedure, attention to keep mean arterial pressure above 50 mmHg was provided.

Brain Natriuretic Peptide

Coronary Artery Bypass Graft Surgery

Cardiac Surgery

Cardiopulmonary Bypass

Desflurane

Outcome

Desflurane inhalational agent administration during the whole cardiac surgical operation with cardiopulmonary bypass versus administration of desflurane inhalational agent before and after cardiopulmonary bypass during the whole period of cardiac surgical operation.

Desflurane Inhalational agent

Desflurane,Brain Natriuretic Peptide and Cardiac Surgery

An Investigation of the Association Between Desflurane Inhalational Agent, Serum Brain Natriuretic Peptide (BNP) Levels and Clinical Outcomes During Coronary Artery Bypass Graft (CABG) Surgery

Serum BNP values were collected from a blood sample of each patient one day before cardiac surgery

Serum BNP values were collected from a blood sample of each patient after cardiac surgery

The collected serum BNP values were compared with each other by repeated measure analysis

A relation between serum BNP values and aortic cross-clamp time

A relation between serum BNP values and cardiopulmonary bypass time

A relation between serum BNP values and use of inotropic support

A relation between serum BNP values and use of Intra-aortic balloon pump

A relation between serum BNP values and duration of mechanical ventilation (>48 hours)

A relation between serum BNP values and development of pneumonia

A relation between serum BNP values and perioperative myocardial infarction

A relation between serum BNP values and cerebrovascular event (stroke or transient ischemic attack) or seizure

A relation between serum BNP values and atrial fibrillation and other atrial rhythm disturbances

A relation between serum BNP values and ventricular rhythm disturbances

A relation between serum BNP values and need for renal replacement therapy (RRT)

A relation between serum BNP values and reoperation secondary to bleeding

A relation between serum BNP values and intensive care unit stay (>3 days)

A relation between serum BNP values and thirty-day mortality

IPD sharing plan includes sharing of the Study Protocol, Statistical Analysis Plan, and Statistical Analysis of the study with researchers upon request via e-mail.

Ayse Baysal

Associate Professor

Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital

Trakya University Faculty of Medicine Hospital

In a prospective, randomized, double-blinded study, desflurane inhalational anesthesia was administered either continuously or intermittently (Group 1; n=60 versus Group 2; n=62).

The observers were blinded to the anesthetic protocol. Caregivers were not blinded, but they did not participate in data collection or data interpretation. Therefore, the study protocol is considered double-blinded, masked to observers.

Patients with acute ischemic stroke with elevated Troponin

Patients with acute ischemic stroke without elevated Troponin

Patients with acute ischemic stroke with elevated Troponin T and pathological ECG and coronary angiography

Patients with acute ischemic stroke without elevated Troponin T and pathological ECG and coronary angiography

Myocardial Infarction

Stroke

Dep. of Neurology, Bern University Hospital, Bern

The Brain Heart Interaction in Acute Stroke

Association is to be determined via multivariate logistic regression. Baseline parameter at inclusion; functional outcome/mortality after 3 months.

University Hospital Inselspital, Berne

Total of 24 cycles of lenalidomide. Subjects received a starting daily dose of 10mg lenalidomide on days 1 through 28 of each 28 day cycle. Subjects initiated lenalidomide 28-100 days post-ASCT.

Total of twenty-four (24) 28-day cycles of Lenalidomide, 10mg, oral tablets, daily.

Maintenance Lenalidomide in Lymphoma

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

Region of Enrollment

Lymphoma sub-type

Dose-limiting toxicity (DLT) is defined as any grade 3 toxicity or higher that occurs during the first 28 days of therapy and is possibly, probably, or definitely related to lenalidomide maintenance.

Total of twenty-four (24) 28-day cycles of Lenalidomide, 10mg, oral tablets, daily

Number of Subjects With Dose-limiting Toxicities

Progression free survival (PFS) is defined as days from start of high dose chemotherapy to first documented progression of disease, death due to any cause or last patient contact.

Progression Free Survival

Overall survival (OS) is defined as days from start of high dose chemotherapy to death due to any cause or last patient contact.

Overall Survival

Overall Study

Jakub Svoboda, MD. Study Principal Investigator

Total of twenty-four (24) 28-day cycles of lenalidomide, 10mg, oral tablets, daily
Lenalidomide: Lenalidomide, 10mg, oral tablets, daily

atrial fibrillation/seizures

Desflurane,Brain Natriuretic Peptide and Cardiac Surgery

The Brain Heart Interaction in Acute Stroke

Maintenance Lenalidomide in Lymphoma

Elm tərəfindən dəstəklənən ən tam dərman bitkiləri bazası